14 days of Premium, free.
Every scanner with live hit rates + the Market Pulse risk flag that tells you when to get defensive. No card required.
Start trial →
Tradestie Institutional Equity Comparison Engine · Market Close Nov 20, 2026
MNOV vs ACHV: Which Stock Is the Better Buy Now?
Deterministic 6-pillar institutional evaluation across valuation multiples, TTM & multi-year operating margins, cash generation, options IV skew, and supply-chain moat.
As of Nov 20, 2026, Medicinova, Inc. (MNOV) is the stronger overall head-to-head candidate over Achieve Life Sciences, Inc. (ACHV) in the Tradestie Institutional Equity Comparison Engine, winning 5–4 core matrix metrics and 4–1 across our 6-pillar institutional scorecard (led by Valuation Multiples, Growth & Scale, Profitability & Quality). MNOV carries a Unified Composite Score of 50.2/100 (HOLD) at $1.31 (8.5x Forward P/E, -1232.2% operating margin), whereas ACHV carries 56.6/100 (HOLD) at $6.78 (35.3x Forward P/E, 0.0% operating margin).
Composite vs. Pillar Nuance: While ACHV currently prints a higher short-term Unified Composite Score (56.6/100 HOLD vs. MNOV 50.2/100 HOLD), MNOV captures the overall institutional head-to-head verdict (5–4 matrix metrics and 4–1 across the 6 pillars) due to superior fundamental profitability (-1232.2% vs. 0.0% operating margin) and revenue trajectory (+12.4% vs. +0.0% YoY).
Technical & Structure Timing Caution: MNOV is currently in a short-term Weinstein Markdown pullback below its falling 50-day moving average (RSI 36.4); meanwhile ACHV trades in a Neutral technical trend (BREAKOUT options phase, RSI 48.1). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.
Standardized multi-year USD domestic revenue schedules are unavailable for foreign-domiciled ADR filing schedules on MNOV vs ACHV. Trailing 12-month operating profitability (MNOV -1232.2% vs ACHV 0.0%) and valuation multiples (MNOV 8.5x vs ACHV 35.3x Forward P/E) are benchmarked directly in Pillar 4 below.
Competes within the Biotechnology value chain with $692.8M market capitalization and 0.0% operating margin.
OpEx & R&D ReinvestmentN/A
90D Engineering Disclosures0 Published
Investor FAQ MNOV vs ACHV Key Questions & Quantitative Answers
As of Nov 20, 2026, Medicinova, Inc. (MNOV) is the stronger overall head-to-head candidate over Achieve Life Sciences, Inc. (ACHV) in the Tradestie Institutional Equity Comparison Engine, winning 5–4 core matrix metrics and 4–1 across our 6-pillar institutional scorecard (led by Valuation Multiples, Growth & Scale, Profitability & Quality). MNOV carries a Unified Composite Score of 50.2/100 (HOLD) at $1.31 (8.5x Forward P/E, -1232.2% operating margin), whereas ACHV carries 56.6/100 (HOLD) at $6.78 (35.3x Forward P/E, 0.0% operating margin). Composite vs. Pillar Nuance: While ACHV currently prints a higher short-term Unified Composite Score (56.6/100 HOLD vs. MNOV 50.2/100 HOLD), MNOV captures the overall institutional head-to-head verdict (5–4 matrix metrics and 4–1 across the 6 pillars) due to superior fundamental profitability (-1232.2% vs. 0.0% operating margin) and revenue trajectory (+12.4% vs. +0.0% YoY). Technical & Structure Timing Caution: MNOV is currently in a short-term Weinstein Markdown pullback below its falling 50-day moving average (RSI 36.4); meanwhile ACHV trades in a Neutral technical trend (BREAKOUT options phase, RSI 48.1). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.
MNOV leads the Growth & Scale pillar: MNOV posts +12.4% YoY revenue growth and +0.0% YoY earnings growth on $935,717 TTM revenue (42.2% gross margin, -1232.2% operating margin), compared with ACHV at +0.0% YoY revenue growth and +0.0% YoY earnings growth on N/A TTM revenue (N/A gross margin, 0.0% operating margin). On trailing 12-month operating scale, MNOV generates $935,717 in USD-normalized revenue versus N/A for ACHV. In operating R&D and SG&A reinvestment, MNOV deploys N/A (0 90-day corporate R&D disclosures) versus N/A (0 disclosures) for ACHV.
MNOV screens cheaper on headline valuation multiples. MNOV trades at 8.5x Forward P/E, 8.5x Trailing P/E, N/M PEG, and 42.5x EV/Revenue (unreported FCF margin), whereas ACHV trades at 35.3x Forward P/E, 35.3x Trailing P/E, 17.68x PEG, and N/M EV/Revenue (unreported FCF margin). Multiples above 150x or negative earnings denominators are marked N/M to avoid distorted accounting comparisons; weigh lower Forward P/E and PEG against MNOV (-24.8% ROE) versus ACHV (-845.0% ROE) capital efficiency.
In options market volatility and institutional positioning, MNOV carries 140.1% implied volatility (50th %ile, Balanced (25th–60th %ile)), unclassified Put/Call open interest, NEUTRAL on-balance volume, and sits in an UNCLASSIFIED options structure phase (0.59β · 38% Vol realized risk). By comparison, ACHV carries 88.3% implied volatility (23rd %ile, Compressed (<25th %ile)), unclassified Put/Call open interest, NEUTRAL on-balance volume, and sits in a BREAKOUT options structure phase (1.73β · 62% Vol realized risk).
Cross-Compare 1-Click Peer Rivalries & Single-Stock Research
Powered by Tradestie Institutional Equity Comparison Engine & standardized corporate financial telemetry. Market close as of Nov 20, 2026. For educational research only; not investment advice.